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Summary
Acute pulmonary embolism (PE) is a common condition frequently associated with a high mortality worldwide. It can be classiﬁed into
non-massive, sub-massive and massive, based on the degree of haemodynamic compromise. Surgical pulmonary embolectomy,
despite having been in existence for over 100 years, is generally regarded as an option of last resort, with expectedly high mortality
rates. Recent advances in diagnosis and recognition of key qualitative predictors of mortality, such as right ventricular stress on echocar-
diography, have enabled the re-exploration of surgical pulmonary embolectomy for use in patients prior to the development of signiﬁ-
cant circulatory collapse, with promising results. We aim to review the literature and discuss the indications, perioperative workup and
outcomes of surgical pulmonary embolectomy in the management of acute PE.
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INTRODUCTION
Pulmonary embolism (PE) is a common clinical condition asso-
ciated with signiﬁcant morbidity and mortality. Surgical pulmon-
ary embolectomy has traditionally been reserved for the most
severely compromised of patients not amenable to medical
therapy. Accurate diagnosis and recognition of speciﬁc biochem-
ical (brain natriuretic peptides and cardiac troponins) and echo-
cardiographic surrogates of haemodynamic stress have improved
risk stratiﬁcation. Consequently, recent studies have demon-
strated impressive outcomes of surgical embolectomy through
careful patient selection.
We provide an overview of acute PE and discuss surgical pul-
monary embolectomy, in terms of indications, perioperative
management and its contemporary role, as part of a multidiscip-
linary approach, in the management of acute PE.
ACUTE PULMONARY EMBOLISM
Incidence and deﬁnition
Acute PE is a common clinical problem, with an estimated in-
cidence of 600 000 cases annually in the USA and accounting
for 50 000 to 200 000 deaths [1]. According to data from the
UK General Practice Research Database (GPRD), the incidence
of PE between 1994 and 2000 was 34.2 per 100 000 patient-
years [2].
In recent times, acute PE has become a matter of public
concern due to the wide dissemination, by the media, of the
so-called economy class syndrome due to a number of dramatic
cases with lethal outcomes as observed across numerous inter-
national airports. The association between pulmonary thrombo-
embolism (PTE) and prolonged air travel, however, has been well
reported in the medical literature for many years [3, 4]. Although
such a risk is still poorly deﬁned, the incidence of severe PTE
during air travel appears to be low. A study of international
ﬂights arriving at the Madrid-Barajas International Airport, over a
period of 6 years, found an incidence of 0.39 episodes of PTE
per million passengers, with all cases involving ﬂights of more
than 6 h duration [5]. Similar observations were seen at airports
in Paris and London [6, 7]. Risk factors for PE also include
obesity, increasing age (mean age with acute PE is 62 years) [8],
cigarette smoking, hypertension, oral contraceptive use [9] and
pregnancy. Conditions limiting mobility such as recent surgery
[10], cardiac failure and respiratory failure, in addition to malig-
nancies (particularly brain, ovarian and pancreatic) [11], have
also been associated with PE. Of the latter, compression of the
inferior vena cava by malignancies have also been associated
with PE. Approximately 20% of patients in the International
Cooperative PE Registry (ICOPER) had idiopathic PE [8].
The use of low-dose subcutaneous unfractionated heparin or
low-molecular-weight heparin (LMWH) in the hospital setting has
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led to a decrease in the incidence of symptomatic venous
thromboembolic disease [12]. A large meta-analysis demonstrated
that the perioperative use of subcutaneous unfractionated heparin
in prophylactic doses (5000 units started 2 h before surgery and
continued every 8 or 12 h) reduced rates of symptomatic PE
(from 2.0 to 1.3%) and fatal PE (from 0.8 to 0.3%) [13].
Despite advances in diagnosis and therapy, acute PE is still
associated with high mortality. In the International Cooperative
Pulmonary Embolism Registry of 2454 consecutive patients, the
overall 3-month mortality rate was 17.4% [8]. Patients with PE
may be divided into two groups based on clinical presentation.
Massive PE, characterized by arterial hypotension (<90 mmHg or
a drop of >40 mmHg for >15 min), and cardiogenic shock, have
an in-hospital mortality of 25 to >50% [8, 14, 15]. Patients with
non-massive PE are normotensive and have a much lower risk
of death (3–15%) [16]. Recent focus on a subset of these normo-
tensive patients with subclinical haemodynamic impairment
(‘sub-massive PE’ cohort), characterized by right ventricle (RV)
dysfunction, has shown increased mortality compared with
normotensive patients without RV compromise [1, 8, 16–18].
Therapeutic options
Current therapeutic options include medical management
(anticoagulation and ﬁbrinolytic therapy), catheter embolectomy
and surgical embolectomy (Table 1).
Anticoagulation with initial unfractionated heparin or LMWH
(e.g. enoxaparin) followed by a vitamin K antagonist (e.g. war-
farin) remains the cornerstone of acute PE therapy. Rapid risk
stratiﬁcation is critical and, in patients with haemodynamic com-
promise, ﬁbrinolysis is recommended as ﬁrst-line treatment
unless major contraindications exist [19] (Table 2). Although ﬁ-
brinolysis has been shown to reduce the risk of death or recur-
rent PE by 55% when compared with heparin [20], it carries a
signiﬁcant risk of intracranial haemorrhage of 3% [8], with overall
major bleeding rates approaching 20% [21]. Patients must be
carefully screened, as absolute contraindications to ﬁbrinolysis
exist in one-third of patients with massive PE [14].
Recent evidence has shown outpatient management of acute
PE in low-risk patients to be a safe alternative, with comparable
rates of hospital readmission, to their inpatient counterparts [22].
Mechanical extraction of pulmonary thrombi via a catheter
device (catheter embolectomy) is a novel therapeutic approach
that has an observed success rate of 86% and major complica-
tions of 2.4% [23]. Distal showering of emboli from proximal clot
Table 1: Treatment options for PE [44]
Indication Contraindication
Anticoagulation Normotensive and normal RV function
INR target 2.5 (range 2.0–3.0)
Clinical scenario Duration of anticoagulation
PE secondary to a
reversible risk factor
3 months, vitamin K antagonist
Unprovoked PE ≥3 months, vitamin K antagonist
Recurrent unprovoked PE Indefinite, vitamin K antagonist
PE and cancer LMWH for the first 3–6 months, followed by indefinite
vitamin K antagonist or LMWH therapy
Thrombolysis Normotensive and RV dysfunction
PE causing haemodynamic compromise
See Table 2
Severely compromised patients requiring
emergency embolectomy
Catheter
embolectomy
Contraindications to thrombolytic therapy
Failure of thrombolytic therapy
Surgical embolectomy is unavailable
Expertise or facility unavailable
Surgical
embolectomy
Failed thrombolytic therapy
Failed catheter embolectomy
Insufficient time for effective thrombolytic therapy in critical patients
Chronic thromboembolism
Active gastrointestinal/surgical site bleeding
INR: international normalized ratio.
Table 2: Contraindications for fibrinolysis and surgical
pulmonary embolectomy
Absolute contraindications Relative contraindications
Fibrinolytic therapy [19, 59]
Haemorrhagic stroke or stroke of
unknown origin at time
Transient ischaemic stroke
in last 6 months
Ischaemic stroke in last 6 months Oral anticoagulant therapy
Central nervous system neoplasms Pregnancy
Recent major trauma/surgery/head
injury within last 3 weeks
Advanced hepatic disease
Gastrointestinal bleeding within last
1 month
Infective endocarditis
Known active bleeding Active peptic ulcer
Traumatic resuscitation
Refractory hypertension
(SBP >180 mmHg)
Traumatic resuscitation
Surgical pulmonary embolectomy [41]
Acute on chronic PE Failed thrombolysis
Active bleeding (GI tract or other
surgical site)
Stroke (ischaemic or
haemorrhagic)
Lack of qualified cardiothoracic
personnel, CPB equipment and
intensive care facility
Critically ill patients
SBP: systolic blood pressure; GI: gastrointestinal; CPB:
cardiopulmonary bypass.
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fragmentation may occur, and recurrence of embolus or incom-
plete embolectomy is more commonly seen than with surgical
embolectomy, placing patients at higher risk of pulmonary
hypertension. Catheter embolectomy is recommended by the
American College of Chest Physicians (ACCP) for use in carefully
selected patients with haemodynamic compromise who fail or
are unable to receive ﬁbrinolytic therapy, and where surgical
embolectomy is unavailable [24].
SURGICAL PULMONARY EMBOLECTOMY
Background
Surgical pulmonary embolectomy was pioneered by
Trendelenburg in 1908. Earlier attempts saw signiﬁcant hypoxic
brain injury in the few patients who survived the procedure.
With the advent of cardiopulmonary bypass (CPB) and the appli-
cation of heparin as an anticoagulant, Sharp [25] became the ﬁrst
surgeon to successfully perform pulmonary embolectomy using
extracorporeal circulation in 1962. Improved diagnostic adjuncts,
surgical techniques and careful patient selection have seen a
decline in mortality from 35 to 19% over a 30-year period [26].
Recent reports have suggested in-hospital mortality from surgical
embolectomy to be as low as 5–6% (Table 3).
Preoperative considerations
Most deaths from massive PE occur within the ﬁrst few hours of
the initial event [27]. Expedient diagnosis and risk stratiﬁcation
are paramount in patients with acute PE. As the clinical diagnosis
of PE is highly unreliable due to the wide spectrum of non-
speciﬁc symptoms and signs, a deﬁnitive diagnosis must be
made prior to surgical embolectomy (Table 4).
Multidetector row spiral computed tomography (CT) pulmon-
ary angiography (CTPA) has now replaced invasive pulmonary
angiography as the primary imaging test for the diagnosis of PE.
Recent evidence supports its use as a stand-alone test in the ex-
clusion of PE, with high predictive values in concordance with
clinical assessment [19, 28]. Identiﬁcation of central surgically ac-
cessible embolism, preferably limited to the proximal main pul-
monary arteries, is required before proceeding to surgery
(Fig. 1). A CT scan also provides useful prognostic information
from imaging of the right ventricle (RV) and left ventricle (LV). In
patients with PE, CT ﬁndings of RV enlargement indicate a 5-fold
increase in 30-day mortality [29].
Apart from conﬁrming PE, CT scan has also been useful in the
detection of concomitant intracardiac pathology, such as para-
doxical embolus trapped within a patent foramen ovale (PFO) or
cardiac tumours (Fig. 2) [19, 30–32]. Further, extracardiac causes
of thromboembolism, such as abdominal or pelvic masses com-
pressing the deep venous system, may be discovered on CT.
Occasionally, this may reveal signiﬁcant concurrent thrombi
within the iliac, femoral or popliteal deep venous systems [30].
Pulmonary sarcoma can rarely mimic PE on CT (Fig. 3) [31].
In the absence of PE, alternative diagnoses such as pneumo-
nia, emphysema, pulmonary mass or aortic disease may be iden-
tiﬁed on the CT scan. Pulmonary angiography, the traditional
gold standard for the diagnosis of PE, is useful when the results
of CTPA are equivocal.
Echocardiography, although not a reliable diagnostic tool for
acute PE, is now recognized as a powerful predictor of increased
mortality in patients with PE through identiﬁcation of those with
RV dysfunction suggestive of early haemodynamic compromise
[8, 16, 17]. This group of patients, with so-called sub-massive PE,
show a 6-fold increase in the relative risk of in-hospital mortality
[33]. However, such indirect signs of PE related to RV overload or
Table 3: Survey of surgical pulmonary embolectomy
results
Year Author No. of
patients
In-hospital mortality
Overall Patients with
preoperative
arrest
1968 Cooley and Beall [60] 11 55% (6) 100% (3/3)
1972 Clarke and Abrams [61] 26 50% (13) 100% (5/5)
1991 Meyer et al. [62] 96 38% (36) 58% (14/24)
1994 Stulz et al. [27] 50 46% (23) 61% (19/31)
1994 Gulba et al. [55] 13 23% (3) Not reported
2002 Aklog et al. [58] 29 10% (3) 100% (1/1)
2004 Yalamanchili [63] 13 8% (1) 50% (1/2)
2005 Sukhija et al. [18] 18 11% (2) Not reported
2005 Leacche et al. [38] 47 6% (3) 33% (2/6)
2006 Spagnolo et al. [42]a 21 0% (0) 0% (0/2)
2008 Kadner et al. [39] 25 8% (2) 25% (2/8)
2010 Carvalho et al. [56] 16 43% (7) 85% (6/7)
2010 Vohra et al. [43] 21 19% (4) Not reported
2011 Fukuda et al. [64] 19 5% (1) 0% (0/4)
2011 Zarrabi et al. [37]a 30 7% (2) 33% (1/3)
aRetrograde pulmonary perfusion used in addition to the standard
antegrade technique.
Table 4: Preoperative investigations
Computed tomography
CTPA is now considered a stand-alone diagnostic tool for PE
Detection of centrally located embolism amenable to surgery
Detects RV enlargement as a poor prognostic marker
May diagnose other intracardiac and extracardiac pathology
Serial imaging to monitor resolution of PE and effectiveness of
treatment
Pulmonary angiography (conventional invasive test)
Reserved for equivocal CTPA outcome
Transthoracic echo cardiography (TTE)
Not a reliable diagnostic tool for PE
Useful in the detection of RV dysfunction; correlates with increased
mortality in PE
Identifies other concomitant intracardiac pathology
Monitors resolution of RV dysfunction; an indirect marker of PE
resolution and response to treatment
Transoesophageal echocardiography (TOE)
Diagnostic tool by direct visualization of central PE
Emergent on-table diagnosis of suspected PE in critically ill patients
taken straight to room
Intraoperative TOE to detect concomitant intracardiac pathology;
with implications for operative strategies
Biochemical markers (troponin and BNP)
Concurrent elevation of troponin and BNP signifies increased
mortality in normotensive PE patients
BNP: brain natriuretic peptide; CTPA: computed tomography
pulmonary angiography.
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dysfunction may be seen in concomitant cardiorespiratory
disease, in the absence of PE. Echocardiography may identify
acute myocardial abnormalities, pericardial tamponade or aortic
dissection, which can also mimic PE [34]. In a compromised
patient with suspected PE, the absence of echocardiographic
signs of RV overload or dysfunction practically excludes the diag-
nosis as a cause of haemodynamic compromise [19].
Echocardiography can identify other concomitant pathologies
such as free-ﬂoating right heart thrombi (FRHTI), PFO or atrial
septal defect (ASD) [17]. FRHTI with acute PE is associated with
high early mortality of 80–100%, and anticoagulation alone is
frequently inadequate, with pulmonary embolectomy often indi-
cated in this situation [19]. Likewise, PFO in a patient with signiﬁ-
cant PE signiﬁes a particularly high risk of death (10-fold
Figure 2: (A) CT showing a ﬁlling defect (arrow) in the right atrium secondary to an embolus trapped within the PFO. (B) CT showing ﬁlling defect in left atrium
caused by same embolus in (A), traversing through PFO. (C and D) Paradoxical embolus traversing through PFO (Reprinted from [30], with permission from
Elsevier).
Figure 1: (A) CTPA showing multiple ﬁlling defects secondary to multiple pulmonary emboli. (B) Multiple fresh extracted pulmonary emboli (Reprinted from
Choong et al. [30], with permission from Elsevier).
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increase) and arterial thromboembolic complications (5-fold
increase) [17].
In patients treated with thrombolysis, a baseline echocardio-
gram is advised. Persistent clinical instability and residual echo-
cardiographic RV dysfunction imply unsuccessful thrombolysis.
In this scenario, rescue surgical embolectomy is observed to have
a lower mortality rate than repeat thrombolysis (7 vs 38%) [35].
Critically, ill patients with contraindications to thrombolysis
who are taken directly to the operating room must have an
emergent transoesophageal echocardiography (TOE) performed
prior to sternotomy to ensure the appropriateness of surgery.
Large central PEs may be directly visualized on TOE. Anecdotally,
in patients who have already received thrombolysis, on-table
TOE may reveal a PE that has signiﬁcantly improved by the time
the patient is prepared for surgery, thereby obviating the need
for operative management. In view of that, some surgeons con-
sider it reasonable for the medical team to proceed with
thrombolysis, providing there are no contraindications, while
waiting for the surgical team to assess the patient. The rationale
is that thrombolysis may provide potential beneﬁts and any po-
tential bleeding risks associated with thrombolysis can be dealt
with in room if necessary.
Elevated cardiac biomarkers, such as troponin and brain natri-
uretic peptide, can identify patients with PE who are likely to
have poorer outcomes treated with anticoagulation therapy
alone [16]. Simultaneous measurements of troponin and brain
natriuretic peptide were found to stratify normotensive PE
patients more accurately than either test alone. PE-related
40-day mortality in patients with concurrent elevation of both
markers >30% [36].
A multidisciplinary approach based on rapid diagnosis and
risk stratiﬁcation is key in identifying PE patients with signiﬁcant
RV dysfunction who are likely to have worse early outcomes,
thereby allowing early surgical management of amenable
patients.
Indications
Most patients with PE do not require pulmonary embolectomy.
Surgical embolectomy is indicated in patients with: (i) massive
PE, conﬁrmed on angiography if possible; (ii) haemodynamic in-
stability despite anticoagulation therapy and resuscitative efforts;
(iii) failure of thrombolytic therapy or a contraindication to its
use and (iv) in critical patients with insufﬁcient time for systemic
thrombolysis to be effective [19, 24].
The decision to proceed to surgical embolectomy must be in
the setting of a deﬁnitive diagnosis, as a clinical diagnosis of PE
is often unreliable. In highly unstable patients taken directly to
the operating room without a deﬁnitive diagnosis, on-table TOE
and colour ﬂow Doppler can help conﬁrm PE.
The traditional recommendation for surgery only in the
most compromised patients, often after failure of medical man-
agement, delays surgery and accounts for the high mortality
Figure 3: Pulmonary sarcoma mimicking PE on the CT scan. (A) CT demonstrating complete occlusion of the right pulmonary artery. (B) Pulmonary arteriogram in
the same patient as A showing total occlusion of the right pulmonary artery, whereas the left pulmonary artery and its branch vessels were normal. (C) The CT
scan showing a massive saddle ‘embolus’ at the bifurcation of the pulmonary artery in another patient. (Reprinted from Choong et al. [30], with permission from
Elsevier).
R
EV
IE
W
C. He et al. / European Journal of Cardio-Thoracic Surgery 1091
rates observed. However, recent interest has focused on pul-
monary embolectomy as ﬁrst-line treatment in haemodynamic-
ally stable patients showing echocardiographic RV dysfunction.
Early surgery in these impending circulatory failure patients has
shown promising results [37, 38].
Failure of thrombolysis. Meneveau et al. [35] found that in
patients with massive PE who failed initial thrombolytic therapy,
pulmonary embolectomy resulted in an in-hospital outcome
superior to that of repeat thrombolysis. Although the risk of
major bleeding was similar between the groups, all bleeding
events in the repeat-thrombolysis group proved fatal. Other
studies also support surgical embolectomy as a successful
treatment strategy in massive PE when compared with medical
treatment, with lower mortality rates, a lower number of
haemorrhagic events and recurrent thrombosis [39].
Concomitant cardiac pathology. Echocardiographic
detection of concomitant FRHTI, PFO or ASD is also indications
for pulmonary embolectomy. FRHTI is considered a sitting time
bomb, with impending PE and potential circulatory collapse,
making surgery time critical. It is associated with high rates
of morbidity and mortality, as discussed earlier. PFO and ASD
allow for paradoxical thromboembolism in the systemic
circulation. Spectacular ‘paradoxical embolus caught red-handed’
has also been reported in the literature, where FRHTI was
found trapped within the PFO, necessitating emergency surgery
(Fig. 4) [30].
Cerebrovascular accident (ischaemic and haemorrhagic).
Ischaemic or haemorrhagic stroke patients who are critically ill
as a result of massive PE may beneﬁt from pulmonary
embolectomy when no alternative rescue procedure is available
[40]. Minimizing the duration on extracorporeal circulation, early
cessation of anticoagulation following the reversal of RV
dysfunction, and the insertion of inferior vena cava (IVC) ﬁlter
were shown to achieve good outcomes in these patients [26].
Contraindications
Pulmonary embolectomy is contraindicated (Table 2) in acute-
on-chronic PE, where there is a persistent high risk of pulmonary
hypertension, right heart failure and intractable pulmonary
haemorrhage. Surgical endarterectomy is indicated in this situ-
ation [41].
Active bleeding, from the gastrointestinal tract or other surgi-
cal site, is another contraindication owing to the signiﬁcant risk
of potentiating further haemorrhage in the setting of hepariniza-
tion while on CPB. However, in stroke patients with fatal PE,
rescue surgical embolectomy may be feasible if no alternative
therapies are available [40].
Management of acute massive PE following failed thromboly-
sis is not well deﬁned. Despite the perceivable concerns of surgi-
cal embolectomy in this cohort, Meneveau et al. [35] showed
that previous thrombolysis is not an absolute contraindication.
Outcomes in surgical embolectomy following failed thrombolysis
were found to be superior to repeat thrombolysis in terms of
lower mortality and recurrence of PE [35].
While haemodynamic instability constitutes the most frequent
indication for surgical embolectomy [26], it is recognized that
out-of-hospital cardiac arrests without restoration of spontaneous
heart beat preoperatively have a particularly dismal prognosis.
Operative technique and complications
We recommend intraoperative TOE for all patients to assess for
the presence of intracardiac pathology, such as PFO or ASD,
which may affect cannulation and myocardial protective and op-
erative strategies.
A median sternotomy is used. The pericardium is entered and
CPB is established using bicaval cannulation and ascending
aortic perfusion after institution of heparin. Other alternative
sites for venous drainage and arterial return may also be con-
templated in accordance with the patient’s condition and sur-
geons’ preference. In the absence of concomitant cardiac
procedures, cardioplegic or ﬁbrillatory arrest and aortic cross-
clamping can be avoided to minimize potential cardiac ischae-
mic injury. The pulmonary trunk is exposed and a longitudinal
arteriotomy starting 1.5 cm distal to the pulmonary valve and
extending to the proximal left pulmonary artery is performed.
Forceps and suction catheters are used to gently extract clots,
under direct vision, where possible. Fogarty catheter extraction
of peripheral clots must be done with great care to avoid injur-
ing the thin-walled pulmonary artery branches. Alternatively, the
pleural spaces are entered and gentle compression of each lung
with concurrent arterial tree saline irrigation can help dislodge
small peripheral clots into larger vessels, and they may then be
suctioned out. This manoeuvre should not be used in patients
on thrombolytic therapy as intractable endobronchial haemor-
rhage may occur. An additional right pulmonary arteriotomy
is made for further clot extraction, if necessary. Following embol-
ectomy, the arteriotomy is closed and the patient is weaned off
CPB. Inotrope assistance is frequently required in patients with
preoperative right ventricular dysfunction.
Figure 4: (A) Echocardiography showing a 9-cm long mass (7 cm long in the
right atrium and 2 cm long in the left atrium), traversing through a PFO. (B)
Nine-cm long embolus removed intact (Reprinted from Choong et al. [30],
with permission from Elsevier).
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Infrequently, retrograde pulmonary perfusion has been used
as an adjunct to the conventional antegrade technique
described above. It may help dislodge clots in the peripheral
pulmonary vasculature not directly visualized. Its proponents
further refer to its ability to prevent air embolism, thereby min-
imizing subsequent lung injury [37, 42].
Recurrent pulmonary embolism. Recurrence of PE is a
serious complication. To date, the efﬁcacy of IVC ﬁlter insertion
after pulmonary embolectomy remains controversial. In ICOPER
patients with massive PE, IVC ﬁlters appeared to reduce
recurrent PE and mortality at 90 days. This is supported by
Meneveau et al. [35] in their study comparing repeat
thrombolysis and rescue embolectomy. Recurrent PE was
responsible for one-third of deaths in the former, while no
recurrence was demonstrated in the surgical group. All surgical
embolectomy patients had IVC insertion prior to sternal closure.
In contrast, Vohra et al. [43] observed no recurrent PE following
surgical embolectomy despite the lack of ﬁlter insertion.
The signiﬁcant mortality arising from re-embolization has
resulted in some surgeons preferring to insert caval ﬁlters where
possible, either at the end of embolectomy or postoperatively
by radiologists.
Current ACCP guidelines recommend vena cava ﬁlter use in the
setting of acute PE if anticoagulation is contraindicated or in the
presence of recurrent venous thrombosis despite adequate anticoa-
gulation [24, 44]. The initial beneﬁcial effect of IVC ﬁlters may be
counterbalanced by an increased risk of deep-vein thrombosis [45].
Massive endobronchial haemorrhage. There are several
reports of massive endobronchial haemorrhage following
pulmonary embolectomy [46–49]. Two aetiological factors have
been suggested: (i) direct mechanical injury to the pulmonary
arterial wall during the act of clot removal and (ii) reperfusion
injury after the re-establishment of pulmonary blood ﬂow, either
during or after CPB. The control of haemorrhage under
heparinized conditions is challenging. Prompt identiﬁcation of
the side or site of arterial injury is vital. Successful management
of this complication has been achieved by: (i) the use of a
double-lumen endotracheal tube for selective collapse of the
lung and segregating haemorrhage into a solitary main-stem
bronchus [50]; (ii) tamponading the airway with an inﬂated
Fogarty catheter [51] and (iii) thoracotomy with staple wedge
resection of the infarcted portion of lung [46]. The immediate
institution of positive end-expiratory pressure (20 cm H2O) may
also aid haemostasis [49].
Postoperative management
Routine postoperative care, as for any cardiac surgery patient, is
instituted. Although most patients can be weaned off CPB, those
requiring signiﬁcant resuscitation leading to embolectomy may
need postoperative mechanical assistance for persistent RV failure.
Renal failure and ischaemic brain injury from inadequate preopera-
tive circulatory state may become apparent in these patients.
In the absence of excessive bleeding, heparin anticoagulation
is commenced 6 h postoperatively and continued until an oral
vitamin K antagonist is therapeutic (INR range 2.0–3.0). The dur-
ation of long-term anticoagulation should be based on three
factors: (i) the risk of recurrence after cessation of treatment; (ii)
the risk of bleeding during treatment and (iii) the patient’s
preference. The recommended duration of anticoagulation
therapy is listed in Table 1.
Surgical outcomes
Without prompt accurate diagnosis and aggressive treatment,
acute PE is frequently fatal. Massive and sub-massive PE remain
a major therapeutic challenge, with mortality rates of up to 60%
in the ﬁrst 6 h of the initial event [8, 52–54].
Surgical pulmonary embolectomy has traditionally been indi-
cated in severely compromised patients who have failed conven-
tional medical management. In a systematic review by Stein
et al. [26], patients who experienced cardiac arrest before pul-
monary embolectomy had a 3-fold increase in surgical mortality
compared with those who did not (59 vs 20%). In the same
study, it was shown that, over a 50-year period, the proportion
of pulmonary embolectomy patients who presented with pre-
operative haemodynamic instability had remained unchanged:
74% from 1961 to 1984, and 74% from 1985 to 2006. Despite
the critical preoperative status of most patients selected for em-
bolectomy, surgical mortality rates have decreased substantially
over time (Table 3). A multidisciplinary approach to diagnosis,
treatment and postoperative care has even seen favourable
results in patients who present with cardiac arrest. A recent
study by Kadner et al. [39] revealed an 8% 30-day mortality rate
in this population.
To date, very few studies have compared medical and surgical
treatment options for patients with massive PE. The two retro-
spective studies that offer such insights both favoured surgical
embolectomy over thrombolysis in terms of lower mortality and
PE recurrence. Among a small cohort of patients with shock and
massive PE, Gulba et al. showed a mortality of 23% in the 13 sur-
gically treated patients compared 33% in the 24 patients who
could not be promptly operated on (thus treated with thromb-
olysis). Recurrent PE rates of 15 and 25% were also observed, re-
spectively. In the other study by Meneveau et al., among 40
patients who failed initial thrombolysis, 14 proceeded to rescue
surgical embolectomy, while 26 were treated by repeat thromb-
olysis. Again, the surgical cohort achieved lower rates of mortal-
ity (7 vs 38%) and PE recurrence (0 vs 35%) compared with the
medical cohort [35, 55]. Despite the positive surgical outcomes,
it is difﬁcult to generalize these observations given the small,
retrospective cohort. A prospective randomized trial would be
ideal, albeit difﬁcult to implement.
Multiple surgical authorities have emphasized the critical im-
portance of early surgical intervention. Recently, several major
centres have liberalized the use of surgical embolectomy to
include haemodynamically stable patients with echocardio-
graphic evidence of moderate-to-severe RV dysfunction [38, 53,
56, 57]. Such ﬁndings are now recognized as strong independent
predictors of RV failure and mortality in patients with PE. Of
note, a retrospective study by Leacche et al. [38] examined 47
such patients who underwent early pulmonary embolectomy
and observed an impressive operative mortality of 6%. An earlier
study from the same institution analysing 29 overlapping patients
showed a mortality of 10% [58]. Similar results have been
demonstrated by Digonnet et al. [57, 58]. The use of retrograde
pulmonary perfusion as an adjunct to antegrade pulmonary
embolectomy has also seen favourable results, with 6 and 0%
in-hospital mortality rates reported by Zarrabi et al. [37]
and Spagnolo et al. [42], respectively. However, comparative
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prospective studies are lacking to establish its role as a routine
surgical technique.
CONCLUSIONS
Recent advances in surgical techniques, coupled with a multidis-
ciplinary approach to diagnosis, risk stratiﬁcation and periopera-
tive care, have signiﬁcantly decreased the mortality associated
with surgical pulmonary embolectomy. Sufﬁcient evidence exists
to support widening its role, from a strictly rescue therapy for
the most severely compromised patients, to those who show
evidence of RV dysfunction in the absence of haemodynamic
collapse.
Conﬂict of interest: none declared.
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